BioMarin resubmits Biologics Licence Application (BLA) for valoctocogene roxaparvovec AAV gene therapy for severe haemophilia A to the FDA

30 September 2022


BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has announced that the Company resubmitted a Biologics Licence Application (BLA) to the U.S. Food and Drug Administration (FDA) for its investigational AAV gene therapy, valoctocogene roxaparvovec, for adults with severe haemophilia A. The resubmission incorporates the Company’s response to the FDA Complete Response (CR) Letter for valoctocogene roxaparvovec gene therapy issued on August 18, 2020, and subsequent feedback, including two-year outcomes from the global GENEr8-1 Phase 3 study and supportive data from five years of follow-up from the ongoing Phase 1/2 dose escalation study.

BioMarin anticipates an FDA response by the end of October on whether the BLA resubmission is complete and acceptable for review. Typically, BLA resubmissions are followed by a six-month review procedure. However, the Company anticipates three additional months of review may be necessary based on the number of data read-outs that will emerge during the procedure. If approved, valoctocogene roxaparvovec would be the first commercially-available gene therapy in the U.S. for the treatment of severe haemophilia A.

Read the full story from BioMarin here.